Treatment of Alternaria keratitis with intrastromal and topical caspofungin in combination with intrastromal, topical, and oral voriconazole

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages

  Neoh, Chin Fen ^a   Leung, Lok ^b   Vajpayee, Rasik B ^c   Stewart, Kay ^a   Kong, David C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^c CENTRE FOR EYE RESEARCH AUSTRALIA   (Australia)

Author keywords

Alternaria; Intrastromal caspofungin; Keratitis; Topical caspofungin; Voriconazole

Indexed keywords

CASPOFUNGIN; CHLORAMPHENICOL; CYCLOSPORIN; HOMATROPINE; NATAMYCIN; OFLOXACIN; OXYCODONE; PARACETAMOL; TEMAZEPAM; VORICONAZOLE;

ADD ON THERAPY; AGED; ALTERNARIA; ALTERNARIA KERATITIS; ANTERIOR EYE CHAMBER; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CORNEAL BIOPSY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; EVENING DOSAGE; FEMALE; FUNGAL EYE INFECTION; GRAFT REJECTION; HUMAN; HUMAN TISSUE; HYPOPYON; INTRAOCULAR PRESSURE; KERATITIS; KERATOPATHY; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; PSEUDOPHAKIA; TREATMENT RESPONSE; VISUAL ACUITY;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; ALTERNARIA; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; EYE INFECTIONS, FUNGAL; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; KERATITIS; PYRIMIDINES; TRIAZOLES;

EID: 79957576759     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P586     Document Type: Article

References (51)

1. FlorCruz NV, Peczon I Jr. Medical interventions for fungal keratitis. Cochrane Database of Systematic Reviews, 2008.
2. Tu EY. Alternaria keratitis: clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin. Cornea 2009;28:116-119. DOI 10.1097/ICO.0b013e31818225f8
3. Ozbek Z, Kang S, Sivalingam J, Rapuano CJ, Cohen EJ, Hammersmith KM. Voriconazole in the management of Alternaria keratitis. Cornea 2006;25:242-4.
4. Azar P, Aquavella JV, Smith RS. Keratomycosis due to an Alternaria species. Am J Ophthalmol 1975;79:881-882.
5. Verma K, Vajpayee RB, Titiyal JS, Sharma N, Nayak N. Post-LASIK infectious crystalline keratopathy caused by Alternaria. Cornea 2005;24: 1018-1020.
6. Kocaturk T, Pineda R 2nd, Green LK, Azar DT. Post-LASIK epithelial dendritic defect associated with Alternaria. Cornea 2007;26:1144-1146. DOI 10.1097/ICO.0b013e31812dfad1
7. Yildiz EH, Ailani H, Hammersmith KM, Eagle RC Jr, Rapuano CJ, Cohen EJ. Alternaria and Paecilomyces keratitis associated with soft contact lens wear. Cornea 2010;29:564-8. DOI 10.1097/ICO.0b013e3181ba0cde
8. Snibson GR. Collagen cross-linking: a new treatment paradigm in corneal disease-a review. Clin Experiment Ophthalmol 2010;38:141-53. DOI 10.1111/j.1442-9071.2010.02228.x
9. Shukla PK, Kumar M, Keshava GB. Mycotic keratitis: an overview of diagnosis and therapy. Mycoses 2008;51:183-99. DOI 10.1111/j.1439-0507.2007.01480.x
10. Ursea R, Tavares LA, Feng MT, McColgin AZ, Snyder RW, Wolk DM. Non-traumatic Alternaria keratomycosis in a rigid gas-permeable contact lens patient. Br J Ophthalmol 2010;94:389-90. DOI 10.1136/bjo.2009.164632
11. Singh D, Verma A. Emedicine. Fungal keratitis. http://emedicine.medscape.com/article/1194167-overview (accessed 2010 Aug 22).
12. Garg P, Gopinathan U, Choudhary K, Rao GN. Keratomycosis: clinical and microbiologic experience with dematiaceous fungi. Ophthalmology 2000;107:574-80.
13. Nosanchuk JD, Casadevall A. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 2006;50:3519-28. DOI 10.1128/AAC.00545-06
14. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004;137:820-5. DOI 10.1016/j.ajo.2003.11.078
15. Lau D, Ferdinands M, Leung L, et al. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study. Arch Ophthalmol 2008;126:343-6. DOI 10.1001/archophthalmol.2007.71
16. Al-Badriyeh D, Leung L, Roydhouse T, et al. Prospective open-label study of the administration of two-percent voriconazole eye drops. Antimicrob Agents Chemother 2009;53:3153-5. DOI 10.1128/AAC.01700-08
17. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005;40:e110-2. DOI 10.1086/430062
18. Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol 2007;143:151-3. DOI 10.1016/j.ajo.2006.07.033
19. Prakash G, Sharma N, Goel M, Titiyal JS, Vajpayee RB. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008;146:56-9. DOI 10.1016/j.ajo.2008.02.023
20. Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004;122: 1687-92. DOI 10.1001/archopht.122.11.1687
21. Kernt M, Kampik A. Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology 2009;258:84-93. DOI 10.1016/j.tox.2009.01.008
22. Intravitreal injection doses. In: Bloom J, ed. Moorfields Eye Hospital NHS Foundation Pharmacists Handbook. 2006. London: Moorfields Pharmaceuticals, 2006:168.
23. Loranne Vella Z, Mallia D, Hardie JG, Bezzina A, Fenech T. Case report. Keratomycosis due to Alternaria alternata in a diabetic patient. Mycoses 2002;45:512-4. DOI 10.1046/j.1439-0507.2002.00806.x
24. Ferrer C, Montero J, Alio JL, Abad JL, Ruiz-Moreno JM, Colom F. Rapid molecular diagnosis of posttraumatic keratitis and endophthalmitis caused by Alternaria infectoria. J Clin Microbiol 2003;41:3358-60. DOI 10.1128/jcm.41.7.3358-3360.2003
25. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15. DOI 10.1128/aac.00163-06
26. Al-Badriyeh D, Leung L, Davies GE, Stewart K, Kong D. Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin. Ann Pharmacother 2009;43: 1139-1142. DOI 10.1345/aph.1M008
27. Kusbeci T, Avci B, Cetinkaya Z, et al. The effects of caspofungin and voriconazole in experimental Candida endophthalmitis. Curr Eye Res 2007;32:57-64. DOI 10.1080/02713680601107157
28. Kernt M, Kampik A. Intraocular caspofungin: in vitro safety profile for human ocular cells. Epub 2010 Feb 19. Mycoses. 2010. DOI 10.1111/j.1439-0507.2009.01853.x
29. Package insert. Cancidas (caspofungin). Whitehouse Station, NJ: Merck & Co, Inc., 2009.
30. How TH, Loo WY, Yow KL, et al. Stability of cefazolin sodium eye drops. J Clin Pharm Ther 1998;23:41-47. DOI 10.1046/j.1365-2710.1998.00136.x
31. Vorwerk CK, Tuchen S, Streit F, Binder L, Hofmüller W, Behrens-Baumann W. Aqueous humor concentrations of topically administered caspofungin in rabbits. Ophthalmic Res 2009;41:102-5. DOI 10.1159/000187627
32. Goldblum D, Fausch K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch Clin Exp Ophthalmol 2007;245:825-33. DOI 10.1007/s00417-006-0460-x
33. Neoh CF, He H, Li J, et al. A rapid and sensitive liquid chromatography/ mass spectrometry (LC/MS) assay for caspofungin in human aqueous humour. Antimicrob Agents Chemother 2010;54:4467-70. DOI 10.1128/aac.00509-10
34. Neoh CF, Lok L, Anant M, et al. Penetration of topically administered 0.5% caspofungin eye drops into human aqueous humor. Antimicrob Agents Chemother 2011;55:1761-3. DOI 10.1128/AAC.01175-10
35. Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol 2007;125:789-93. DOI 10.1001/archopht.125.6.789
36. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008;46:2620-9. DOI 10.1128/jcm.00566-08
37. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57. DOI 10.1086/375080
38. Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother 2005;49:1359-63. DOI 10.1128/AAC.49.4.1359-1363.2005
39. Ozturk F, Yavas GF, Kusbeci T, et al. Efficacy of topical caspofungin in experimental Fusarium keratitis. Cornea 2007;26:726-8. DOI 10.1097/ICO.0b013e3180553b9d
40. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-40. DOI 10.1016/j.ajo.2004.08.077
41. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005;140:552-554. DOI 10.1016/j.ajo.2005.03.030
42. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005;40:e46-8. DOI 10.1086/427753
43. Aydin S, Ertugrul B, Gultekin B, Uyar G, Kir E. Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy. BMC Infect Dis 2007;7:87.DOI 10.1186/1471-2334-7-87
44. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005;41:e27-8. DOI 10.1086/431761
45. Spriet I, Delaere L, Lagrou K, Peetermans WE, Maertens J, Willems L. Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. J Antimicrob Chemother 2009;64:877-8. DOI 10.1093/jac/dkp306
46. Yildiran ST, Mutlu FM, Saracli MA, et al. Fungal endophthalmitis caused by Aspergillus ustus in a patient following cataract surgery. Med Mycol 2006;44:665-9. DOI 10.1080/13693780600717161
47. Hurtado-Sarrio M, Duch-Samper A, Cisneros-Lanuza A, Diaz-Llopis M, Peman-Garcia J, Vazquez-Polo A. Successful topical application of caspofungin in the treatment of fungal keratitis refractory to voriconazole. Arch Ophthalmol 2010;128:941-2. DOI 10.1001/archophthalmol.2010.110
48. Product Information. Caspofungin. Electronic Medicines Compendium. http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=12843#SHELF_LIFE (accessed 2010 Aug 22).
49. Health Purchasing Victoria. Health Purchasing Victoria Tender (2010- 2012). http://www.hpv.org.au/ (accessed 2010 Nov 3).
50. Johns Hopkins Points of Care Information Technology. ABX Guide. http://hopkins-abxguide.org/antibiotics/antifungal/caspofungin_acetate.html?contentInstanceId=254891 (accessed 2010 Nov 3).
51. Shalit I, Shadkchan Y, Mircus G, Osherov N. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med Mycol 2009;47:457-62. DOI 10.1080/13693780802232910